VIVUS, Inc. (NASDAQ:VVUS) – Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use

Boston, MA 09/19/2014 (wallstreetpr) – Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the nod by the U.S. Food and Drug Administration to be used 15 minutes earlier. It is crucial to point out here that this drug was already approved by the FDA, but only to be used 30 minutes before sexual activity.

First FDA-Approved ED Drug to be used 15 minutes prior

The developers of this drug said yesterday that Stendra is the first erectile dysfunction drug which is approved by FDA to be used just 15 minutes before intercourse.

Meanwhile, the ED drug of Pfizer Inc. (NYSE:PFE), Viagra needs to be taken one hour prior. Stendra was given FDA approval in the year 2012 and is accessible to people in various dosages, viz. 200 mg, 100 mg and 50 mg. VIVUS, Inc. (NASDAQ:VVUS) and Auxilium said that Stendra can be consumed by males without/with food and also with up to three drinks of alcohol.

Among various drugs approved by the USFDA for treating erectile dysfunction, Viagra is among the most commonly used and recognized drug across the world.

About Stendra

Stendra is the drug belonging to the family of phosphodiesterase type 5 inhibitors. This class of drugs caters particularly to the erectile dysfunction patients, whereby, they can enhance blood flow in the direction of penis.

Rights of Stendra for Vivus and Auxilium

While VIVUS, Inc. (NASDAQ:VVUS) holds the commercial rights for this drug for ED across the world (leaving aside a few Asian nations), Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), in the meanwhile; holds exclusive marketing rights for Stendra in Canada and the U.S.

Sanofi SA (ADR) (NYSE:SNY) is responsible for commercialization of Stendra in Turkey, Middle East and Africa, apart from Commonwealth of Autonomous Countries, which also includes Russia.

In the European Union, Stendra is sold under the commercial name “Spendra.”

Please make sure to read and completely understand our disclaimer at We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email ( or his Google+ page (

Recent Stories

SignUp Now For Our Featured Newsletter